| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9603796 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11369566 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2029
(5 years from now) | |
| US9205048 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2029
(5 years from now) | |
| US9233068 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders |
Dec, 2029
(5 years from now) | |
| US8318817 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2030
(6 years from now) | |
| US9220796 | ALK ABELLO | Sterilization of ciprofloxacin composition |
Jul, 2035
(11 years from now) | |
| US11040004 | ALK ABELLO | Otic gel formulations for treating otitis externa |
Nov, 2037
(13 years from now) | |
| US11246863 | ALK ABELLO | Ciprofloxacin otic composition and kits and method for using same |
Nov, 2038
(14 years from now) | |
Otiprio is owned by Alk Abello.
Otiprio contains Ciprofloxacin.
Otiprio has a total of 8 drug patents out of which 0 drug patents have expired.
Otiprio was authorised for market use on 10 December, 2015.
Otiprio is available in injectable, suspension;otic dosage forms.
Otiprio can be used as the treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus, treatment of pediatric patients with otitis media with effusion undergoing tympanostomy tube placement, treatment of otic infection or inflammation.
The generics of Otiprio are possible to be released after 27 November, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 10, 2018 |
| New Indication(I-770) | Mar 02, 2021 |
Drugs and Companies using CIPROFLOXACIN ingredient
Market Authorisation Date: 10 December, 2015
Treatment: Treatment of pediatric patients with otitis media with effusion undergoing tympanostomy tube placement; Treatment of otic infection or inflammation; The treatment of acute otitis externa in patients 6...
Dosage: INJECTABLE, SUSPENSION;OTIC
OTIPRIO family patents
